- Home
- ACB vs ZNTL Comparison
ACB vs ZNTL Comparison
Compare ACB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- ZNTL
- Stock Information
- Founded
- ACB 2013
- ZNTL 2014
- Country
- ACB Canada
- ZNTL United States
- Employees
- ACB N/A
- ZNTL N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- ZNTL Health Care
- Exchange
- ACB Nasdaq
- ZNTL Nasdaq
- Market Cap
- ACB 313.9M
- ZNTL 105.8M
- IPO Year
- ACB N/A
- ZNTL 2020
- Fundamental
- Price
- ACB $4.59
- ZNTL $1.32
- Analyst Decision
- ACB
- ZNTL Buy
- Analyst Count
- ACB 0
- ZNTL 7
- Target Price
- ACB N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- ACB 1.7M
- ZNTL 1.3M
- Earning Date
- ACB 08-06-2025
- ZNTL 08-08-2025
- Dividend Yield
- ACB N/A
- ZNTL N/A
- EPS Growth
- ACB N/A
- ZNTL N/A
- EPS
- ACB 0.03
- ZNTL N/A
- Revenue
- ACB $238,837,444.00
- ZNTL $26,865,000.00
- Revenue This Year
- ACB $12.22
- ZNTL N/A
- Revenue Next Year
- ACB $7.36
- ZNTL N/A
- P/E Ratio
- ACB $158.46
- ZNTL N/A
- Revenue Growth
- ACB 27.32
- ZNTL N/A
- 52 Week Low
- ACB $3.42
- ZNTL $1.01
- 52 Week High
- ACB $7.20
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- ACB 47.92
- ZNTL 50.56
- Support Level
- ACB $4.39
- ZNTL $1.15
- Resistance Level
- ACB $4.61
- ZNTL $1.39
- Average True Range (ATR)
- ACB 0.25
- ZNTL 0.10
- MACD
- ACB 0.01
- ZNTL -0.00
- Stochastic Oscillator
- ACB 57.40
- ZNTL 45.12
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.